BD Expands from Cancer Discovery and Diagnosis into Post-Treatment Monitoring with Acquisition of Cytognos from Vitro S.A.
Go back to BD Expands from Cancer Discovery and Diagnosis into Post-Treatment Monitoring with Acquisition of Cytognos from Vitro S.A.| Becton Dickinson (NYSE: BDX) | Delayed: 181.84 +1.14 (0.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $180.70 | 52 Week High | $181.76 | |||
| Open | $182.40 | 52 Week Low | $129.50 | |||
| Day High | $182.83 | P/E | 38.77 | |||
| Day Low | $180.75 | EPS | $4.69 | |||
| Volume | 219,260 | |||||
